Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Lindsley

Showing results (241-250 of 570) with videos related to

Pageof 57
Sort By:
ACS Chemical Neuroscience|November 16, 2020
Restoring Agonist Function at a Chemogenetically Modified M<sub>1</sub> Muscarinic Acetylcholine ReceptorElham Khajehali, Sophie Bradley, Emma T van der Westhuizen, et al.
Bioorganic & Medicinal Chemistry Letters|March 10, 2009
Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1 specificityJana A Lewis, Sarah A Scott, Robert Lavieri, et al.
The Journal of Allergy and Clinical Immunology|December 10, 2019
Abnormal Peyer patch development and B-cell gut homing drive IgA deficiency in Kabuki syndromeGenay O Pilarowski, Tareian Cazares, Li Zhang, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 23, 2015
Competition and allostery govern substrate selectivity of cyclooxygenase-2Michelle M Mitchener, Daniel J Hermanson, Erin M Shockley, et al.
ACS Medicinal Chemistry Letters|September 16, 2014
Discovery and Characterization of ML398, a Potent and Selective Antagonist of the D4 Receptor with in Vivo ActivityCynthia B Berry, Michael Bubser, Carrie K Jones, et al.
ACS Chemical Neuroscience|April 24, 2018
PF-06827443 Displays Robust Allosteric Agonist and Positive Allosteric Modulator Activity in High Receptor Reserve and Native SystemsSean P Moran, Hyekyung P Cho, James Maksymetz, et al.
Advances in Therapy|May 19, 2025
Effectiveness and Safety of Tezepelumab in a Diverse Population of US Patients with Severe Asthma: Initial Results of the PASSAGE StudyNjira L Lugogo, Praveen Akuthota, Kaharu Sumino, et al.
ACS Chemical Biology|December 22, 2009
In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitorsJijun Hao, Joshua N Ho, Jana A Lewis, et al.
Neuron|November 19, 2019
mGlu<sub>2</sub> and mGlu<sub>3</sub> Negative Allosteric Modulators Divergently Enhance Thalamocortical Transmission and Exert Rapid Antidepressant-like EffectsMax E Joffe, Chiaki I Santiago, Kendra H Oliver, et al.
Journal of Medicinal Chemistry|March 1, 2013
Development of dual PLD1/2 and PLD2 selective inhibitors from a common 1,3,8-Triazaspiro[4.5]decane Core: discovery of Ml298 and Ml299 that decrease invasive migration in U87-MG glioblastoma cellsMatthew C O'Reilly, Sarah A Scott, Kyle A Brown, et al.
Pageof 57

Showing results (241-250 of 570) with videos related to

Sort By:
Pageof 57
ACS Chemical Neuroscience|November 16, 2020
Restoring Agonist Function at a Chemogenetically Modified M<sub>1</sub> Muscarinic Acetylcholine ReceptorElham Khajehali, Sophie Bradley, Emma T van der Westhuizen, et al.
Bioorganic & Medicinal Chemistry Letters|March 10, 2009
Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1 specificityJana A Lewis, Sarah A Scott, Robert Lavieri, et al.
The Journal of Allergy and Clinical Immunology|December 10, 2019
Abnormal Peyer patch development and B-cell gut homing drive IgA deficiency in Kabuki syndromeGenay O Pilarowski, Tareian Cazares, Li Zhang, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 23, 2015
Competition and allostery govern substrate selectivity of cyclooxygenase-2Michelle M Mitchener, Daniel J Hermanson, Erin M Shockley, et al.
ACS Medicinal Chemistry Letters|September 16, 2014
Discovery and Characterization of ML398, a Potent and Selective Antagonist of the D4 Receptor with in Vivo ActivityCynthia B Berry, Michael Bubser, Carrie K Jones, et al.
ACS Chemical Neuroscience|April 24, 2018
PF-06827443 Displays Robust Allosteric Agonist and Positive Allosteric Modulator Activity in High Receptor Reserve and Native SystemsSean P Moran, Hyekyung P Cho, James Maksymetz, et al.
Advances in Therapy|May 19, 2025
Effectiveness and Safety of Tezepelumab in a Diverse Population of US Patients with Severe Asthma: Initial Results of the PASSAGE StudyNjira L Lugogo, Praveen Akuthota, Kaharu Sumino, et al.
ACS Chemical Biology|December 22, 2009
In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitorsJijun Hao, Joshua N Ho, Jana A Lewis, et al.
Neuron|November 19, 2019
mGlu<sub>2</sub> and mGlu<sub>3</sub> Negative Allosteric Modulators Divergently Enhance Thalamocortical Transmission and Exert Rapid Antidepressant-like EffectsMax E Joffe, Chiaki I Santiago, Kendra H Oliver, et al.
Journal of Medicinal Chemistry|March 1, 2013
Development of dual PLD1/2 and PLD2 selective inhibitors from a common 1,3,8-Triazaspiro[4.5]decane Core: discovery of Ml298 and Ml299 that decrease invasive migration in U87-MG glioblastoma cellsMatthew C O'Reilly, Sarah A Scott, Kyle A Brown, et al.
Pageof 57